Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats

Journal of Neural Transmission

Volumn 118, Issue 12, 2011, Pages 1717-1725

  Grunblatt E ^a,d   Schmidt, W J ^b   Scheller, D K A ^c   Riederer, P ^a   Gerlach, M ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UCB PHARMA   (Belgium)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

6 Hydroxydopamine; Continuous; Dyskinesia; Gene chip; Gene expression; l DOPA; Microarray; Parkinson's disease; Pulsatile; Quantitative RT PCR; Rotigotine

Indexed keywords

ALPHA TUBULIN; BETA ACTIN; GLUTAMATE RECEPTOR 2; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LEVODOPA; NEUROTROPHIN 3; OROTIDINE 5' PHOSPHATE DECARBOXYLASE; OXIDOPAMINE; RNA 18S; ROTIGOTINE; SEROTONIN RECEPTOR; SOMATOMEDIN B; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DYSKINESIA; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; MALE; MICROARRAY ANALYSIS; MOTOR PERFORMANCE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTONINERGIC TRANSMISSION; SUBSTANTIA NIGRA;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; FUNCTIONAL LATERALITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; LEVODOPA; MALE; NERVE TISSUE PROTEINS; NEUROTROPHIN 3; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PULSATILE FLOW; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84855185567     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0552-y     Document Type: Article

References (31)

1. Alam M, Schmidt WJ (2004) L-DOPA reverses the hyperkinetic behaviour and rigidity in rotenone-treated rats. Behav Brain Res 153:439-446 (Pubitemid 38953119)
2. SC Apfel 1999 Neurotrophic factors in peripheral neuropathies: therapeutic implications Brain Pathol 9 393 413 10219753 10.1111/j.1750-3639. 1999.tb00234.x 1:STN:280:DyaK1M3jsFWmuw%3D%3D (Pubitemid 29157723)
3. CM Baldwin GM Keating 2007 Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease CNS Drugs 21 1039 1055 18020483 10.2165/00023210-200721120-00007 1:CAS:528:DC%2BD1cXnvFCnuw%3D%3D (Pubitemid 350136786)
4. JM Brotchie 2005 Nondopaminergic mechanisms in levodopa-induced dyskinesia Mov Disord 20 919 931 16007614 10.1002/mds.20612 (Pubitemid 41419505)
5. MA Cenci 2002 Transcription factors involved in the pathogenesis of l-DOPA-induced dyskinesia in a rat model of Parkinson's disease Amino Acids 23 105 109 12373525 10.1007/s00726-001-0116-4 1:CAS:528:DC%2BD38Xns1Gns7c%3D
6. MA Cenci 2007 Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia Trends Neurosci 30 236 243 17400300 10.1016/j.tins.2007.03.005 1:CAS:528:DC%2BD2sXkslent7s%3D (Pubitemid 46654236)
7. MA Cenci CS Lee A Bjorklund 1998 l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur J Neurosci 10 2694 2706 9767399 10.1046/j.1460-9568.1998. 00285.x 1:STN:280:DyaK1M7ksFKrsA%3D%3D (Pubitemid 28362576)
8. TN Chase 2004 Striatal plasticity and extrapyramidal motor dysfunction Parkinsonism Relat Disord 10 305 313 15196510 10.1016/j.parkreldis.2004.02.012 (Pubitemid 38757812)
9. Elshoff JP, Cawello W, Braun M, Horstmann R (2006) Stable rotigotine plasma concentrations over 24 hours in patients with early-stage Parkinson's disease after once-daily transdermal administration of rotigotine (Neupro (R)). Lippincott Williams & Wilkins, Baltimore, pp 293
10. N Giladi B Boroojerdi AD Korczyn DJ Burn CE Clarke AH Schapira 2007 Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole Mov Disord 22 2398 2404 17935234 10.1002/mds.21741 (Pubitemid 351155987)
11. E Grünblatt S Hoyer P Riederer 2004 Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease J Neural Transm 111 367 386 14991460 10.1007/s00702-003-0030-x (Pubitemid 38316611)
12. E Grünblatt S Mandel J Jacob-Hirsch, et al. 2004 Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes J Neural Transm 111 1543 1573 15455214 10.1007/s00702-004-0212-1 (Pubitemid 40068786)
13. S Gu H Huang J Bi Y Yao T Wen 2009 Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson's disease rat model Brain Res 1257 1 9 19111525 10.1016/j.brainres.2008.12.016 1:CAS:528:DC%2BD1MXitVOqs7g%3D
14. C Guigoni E Doudnikoff Q Li B Bloch E Bezard 2007 Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates Neurobiol Dis 26 452 463 17350277 10.1016/j.nbd.2007.02.001 1:CAS:528: DC%2BD2sXkt1aitro%3D (Pubitemid 46561343)
15. CP Jacob E Koutsilieri J Bartl, et al. 2007 Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease J Alzheimers Dis 11 97 116 17361039 1:CAS:528:DC%2BD2sXisVGju7c%3D (Pubitemid 46376714)
16. Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 20:(Suppl 11):S11-S16 (Pubitemid 40846906)
17. P Jenner 2008 Molecular mechanisms of l-DOPA-induced dyskinesia Nat Rev Neurosci 9 665 677 18714325 10.1038/nrn2471 1:CAS:528:DC%2BD1cXhtVSjurvP
18. C Konradi JE Westin M Carta ME Eaton K Kuter A Dekundy M Lundblad MA Cenci 2004 Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia Neurobiol Dis 17 219 236 15474360 10.1016/j.nbd.2004.07.005 1:CAS:528: DC%2BD2cXotlSlsbk%3D (Pubitemid 39345778)
19. Z Li Y Hu Q Zhu J Zhu 2008 Neurotrophin-3 reduces apoptosis induced by 6-OHDA in PC12 cells through Akt signaling pathway Int J Dev Neurosci 26 635 640 18462913 10.1016/j.ijdevneu.2008.03.009 1:CAS:528:DC%2BD1cXoslOnt70%3D
20. T Maeda K Nagata Y Yoshida K Kannari 2005 Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA Brain Res 1046 230 233 15894297 10.1016/j.brainres.2005.04.019 1:CAS:528:DC%2BD2MXltVOlt7w%3D (Pubitemid 40775894)
21. GA Metz A Tse M Ballermann LK Smith K Fouad 2005 The unilateral 6-OHDA rat model of Parkinson's disease revisited: an electromyographic and behavioural analysis Eur J Neurosci 22 735 744 16101755 10.1111/j.1460-9568.2005.04238.x (Pubitemid 41192283)
22. M Morelli S Fenu A Cozzolino G Di Chiara 1991 Positive and negative interactions in the behavioural expression of D1 and D2 receptor stimulation in a model of Parkinsonism: role of priming Neuroscience 42 41 48 1830642 10.1016/0306-4522(91)90148-H 1:CAS:528:DyaK3MXlvVSltLk%3D
23. JG Nutt 2007 Continuous dopaminergic stimulation: is it the answer to the motor complications of Levodopa? Mov Disord 22 1 9 16958130 10.1002/mds.21060 (Pubitemid 46382666)
24. Paxinos G, Watson C (1986) The rat brain in sterotaxic coordinates. Academic Press, London
25. WJ Schmidt H Lebsanft M Heindl M Gerlach E Grünblatt P Riederer A Mayerhofer DK Scheller 2008 Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements J Neural Transm 115 1385 1392 18726139 10.1007/s00702-008-0102-z 1:CAS:528:DC%2BD1cXhtFensbfP
26. V Sgambato-Faure V Buggia F Gilbert D Levesque AL Benabid F Berger 2005 Coordinated and spatial upregulation of arc in striatonigral neurons correlates with l-dopa-induced behavioral sensitization in dyskinetic rats J Neuropathol Exp Neurol 64 936 947 16254488 10.1097/01.jnen.0000186922.42592.b7 1:CAS:528:DC%2BD2MXht1Kktb7N (Pubitemid 41668923)
27. M Steiger 2008 Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease Eur J Neurol 15 6 15 18042245 1:STN:280:DC%2BD1c%2FgsFelsQ%3D%3D
28. Stockwell KA, Scheller DK, Smith LA, Rose S, Iravani MM, Jackson MJ, Jenner P (2010) Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets. Exp Neurol 221:79-85
29. B Valastro A Dekundy M Krogh M Lundblad P James W Danysz G Quack MA Cenci 2007 Proteomic analysis of striatal proteins in the rat model of l-DOPA-induced dyskinesia J Neurochem 102 1395 1409 17532790 10.1111/j.1471-4159.2007.04655.x 1:CAS:528:DC%2BD2sXhtVOqtLrP (Pubitemid 47174246)
30. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3, RESEARCH0034
31. von Bohlen und Halbach O, Minichiello L, Unsicker K (2005) Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra. FASEB J 19:1740-1742 (Pubitemid 41429548)